A Saanich-based pharmaceutical company saw its valuation double in early market trading this morning following the results of a clinical trial.

Aurinia Pharmaceuticals rose to a US $2 billion market cap at $22 per share more than doubling its $11 trading range seen earlier in the week. The stock is curently trading in the $16 range representing a market valuation of $1.5 billion.

The company's trial drug voclosporin showed promising effects during an AURURA Phsae 3 clinical study involving individuals with lupus nephritis (LN), an inflammation of the kidney caused by lupus erythematosus.

“This extraordinary pivotal data confirms voclosporin’s ability to achieve statistically significant improvements in clinically meaningful endpoints for this complex disease, with a comparable safety profile to the current standard of care,” said Neil Solomons, M.D., Chief Medical Officer of Aurinia. “This data represents a significant advance for people living with LN, which can lead to irreversible kidney damage, eventual kidney failure and death.”

Aurinia plans to submit an application to the Federal Drug Administration by mid-2020.

Located at Saanich's Vancouver Island Technology Park, a key real-estate holding and technology incubator of the University of Victoria, Aurinia is a major player in the B.C. Capital's technology and pharmaceutical industry. C

Receive Citified's timely real-estate news straight to your inbox. Sign up for our newsletter.

© Copyright 2019 by Citified.ca. All rights reserved.

 Article resources

• Looking for a new-build home or commercial space in Victoria? Use Citified to research new-build condos, rentals and commercial spaces
• Follow Citified on  Twitter
• Connect with Citified on  Facebook:
   

Langford's housing push delivers 2,000 apartments as Capital builds out of tight rental market